Country
United States
Bamlanivimab, a monoclonal antibody directed against the coronavirus spike protein, has been cleared by the US Food and Drug Administration for use in patients with mild-to- moderate Covid-19.
Full text available to subscribers only. Click here for information on subscribing to MedNous.